SCHEMBL5437598

SCHEMBL5437598

CCc1cnc2c(n1)c(=O)n(C)c(=O)n2C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.51
HSD17B10 Q99714 3/20 0.51
LMNA P02545 2/20 0.51
CASP1 P29466 1/20 0.51
CASP7 P55210 1/20 0.51
ALDH1A1 P00352 5/20 0.49
MAPT P10636 3/20 0.49
HPGD P15428 3/20 0.47
HTT P42858 2/20 0.47
JAK2 O60674 1/20 0.47
PAX8 Q06710 1/20 0.47
GAA P10253 3/20 0.45
MEN1 O00255 1/20 0.45
USP2 O75604 1/20 0.45
RECQL P46063 1/20 0.45
KMT2A Q03164 1/20 0.45
POLB P06746 2/20 0.43
THRB P10828 1/20 0.43
BLM P54132 1/20 0.43
ADORA2A P29274 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6323440 0.86 KDM4E (0.50) KDM4EHSD17B10LMNACASP1CASP7
SCHEMBL7528477 0.86 KDM4E (0.50) KDM4EHSD17B10LMNACASP1CASP7
SCHEMBL6323491 0.80 KDM4E (0.64) KDM4EHSD17B10LMNACASP1CASP7
SCHEMBL5445042 0.78 KDM4E (0.56) KDM4EHSD17B10LMNACASP1CASP7
SCHEMBL6317201 0.78 KDM4E (0.41) KDM4EHSD17B10LMNACASP1CASP7
SCHEMBL5439523 0.77 KDM4E (0.58) KDM4EHSD17B10LMNACASP1CASP7
SCHEMBL6315801 0.77 ALDH1A1 (0.51) KDM4EHSD17B10LMNACASP1CASP7
SCHEMBL5440119 0.77 ALDH1A1 (0.51) KDM4EHSD17B10LMNACASP1CASP7
SCHEMBL6315272 0.76 ALDH1A1 (0.46) KDM4EHSD17B10LMNACASP1CASP7
Bromide SCHEMBL7529525 0.76 KDM4E (0.53) KDM4EHSD17B10LMNACASP1CASP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070043000-A1 Immunosuppresive effects of pteridine derivatives 4 AZA BIOSCIENCE NV (BE) 2007-02-22 US disclosed
US-6946465-B2 Immunosuppressive effects of pteridine derivatives 4 AZA BIOSCIENCE NV (BE) 2005-09-20 US disclosed
EP-1479682-A1 Immunosuppressive effects of pteridine derivatives 4 AZA Bioscience nv (BE) 2004-11-24 EP disclosed
US-20030236255-A1 Immunosuppressive effects of pteridine derivatives 4 AZA BIOSCIENCE NV (BE) 2003-12-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043000-A1 Immunosuppresive effects of pteridine derivatives TPMT, FKBP5, RRP15 KDM4E 1686/4885HSD17B10 3757/4885LMNA 3813/4885
US-20030236255-A1 Immunosuppressive effects of pteridine derivatives TPMT, FKBP5, RRP15 KDM4E 1278/4885HSD17B10 3654/4885LMNA 3699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.